Background and objectiveMolecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed multi-omic analysis of UTUC tumors to identify molecular features associated with disease recurrence and response to immune checkpoint blockade (ICB). MethodsTargeted DNA

No Abstract

No Abstract

No Abstract

Background and objectiveTesticular germ cell tumors (TGCTs) are globally rare, although incidence significantly varies across global geographic regions and ethnicities. Recent decades have seen an unexplained increase in incidence. This review investigates the changing epidemiology of TGCT and identifies key risk factors. MethodsA systematic review following the Preferred Reporting Items for Systematic

It has been shown that magnetic resonance imaging (MRI) guidance versus computed tomography (CT) guidance for aggressive margin-reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces acute toxicity, but the longer-term benefits are unknown. We performed a secondary analysis of MIRAGE, a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer, to determine

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

The authors regret about typological errors in the article found by Feng Qi as published in the letter to the editor of July 25, 2024 in European Urology.

Background and objectiveThe treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide clinicians with a practical guide for selecting first- and second-line treatments on the basis of current evidence. MethodsWe critically evaluated systemic treatment strategies for mRCC. A comprehensive

No Abstract

Background and objectiveLymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted a clinically integrated randomized trial comparing limited versus extended pelvic LND (PLND) during radical prostatectomy and previously reported comparable biochemical recurrence (BCR) rates. We report updated

No Abstract

No Abstract

Section snippets General principles for SoMe useThere are ten general principles that urologists should follow when using SoMe platforms (Fig. 1) [1]. Physicians should clearly state their role and align their online behavior with professional standards. It is essential to protect patient privacy by avoiding identifiable information and discussing treatment details only with explicit consent. To prevent

Section snippets Metastatic hormone-sensitive prostate cancer (mHSPC)The debate concerning the scientific accuracy and negative connotations of the word “castration” for patients has been discussed previously [3], [4] and is clearly a prominent example of the powers—positive and negative—mentioned above. In particular, we believe that the word “castration” is difficult for patients, partners, and families

No Abstract

No Abstract

No Abstract

No Abstract

Background and objectiveBiparametric magnetic resonance imaging (bpMRI), excluding dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), is a potential replacement for multiparametric MRI (mpMRI) in diagnosing clinically significant prostate cancer (csPCa). An extensive international multireader multicase observer study was conducted to assess the noninferiority of bpMRI to mpMRI in csPCa

No Abstract

Background and objectiveThis review aims to provide an overview of novel diagnostic and therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers within prospective phase 1–2 clinical trials, summarizing progresses and future directions. MethodsA systematic search was conducted using the PubMed/MEDLINE and ClinicalTrials.gov databases for original prospective research

No Abstract

No Abstract

No Abstract

Section snippets One size does not fit all: the importance of biomarkersOne of the themes from the review by Francini et al [1] that should be highlighted is the importance of biomarkers. Several new therapies are approved for biomarker-selected patients. When the right biomarker is present, patients have a better chance of deriving greater benefit from biomarker-directed therapy. In PROPEL, the hazard

The authors regret that four incorrect estimates pertaining to adverse event (AE) incidence were stated in the text, discrepant from the corresponding tables where correct estimates were included. Specifically, incorrect values were stated in the text for incidence of the following treat treatment-related AEs: 1) AEs of any grade, 2) grade 3-4 AEs, 3) grade 3-4 AST events, and 4) grade 3-4 ALT events

No Abstract

No Abstract

No Abstract

No Abstract

Background and objectiveInnovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results

No Abstract

No Abstract

No Abstract

Background and objectiveDelivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the safety of such a schedule. MethodsRAIDER is an international phase 2 noncomparative randomised controlled trial (ISRCTN26779187). Patients with unifocal T2-T4a urothelial bladder

Decipher is a tissue-based genomic classifier (GC) developed and validated in the post–radical prostatectomy (RP) setting as a predictor of metastasis. We conducted a prospective randomized controlled cluster-crossover trial assessing the use of Decipher to determine its impact on adjuvant treatment after RP.

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Immunotherapy (ICIs) remains a mainstay for treatment of advanced clear-cell renal cell carcinoma (ccRCC). Biomarker analyses have demonstrated that gene expression profiles are associated with regimen-specific outcomes. These transcriptomic analyses used mixed sample cohorts (primary and metastatic tumor specimens) and it is unknown whether the clinical relevance of transcriptomic signatures is impacted

The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations ushered in the era of targeted therapy for bladder cancer. In this review, we summarize the effects of FGFR pathway alterations in oncogenesis, clinical data supporting FGFR inhibitors in the management of bladder cancer, and the challenges that remain.

No Abstract

No Abstract

No Abstract

Management of metastatic prostate cancer (mPCa) presents significant challenges. In this systematic review, meta-analysis, and meta-regression, the efficacy, safety, and quality of life (QoL) outcomes of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) utilising lutetium-177 ([177Lu]Lu-PSMA) and actinium-225 ([225Ac]Ac-PSMA) were assessed.

Active surveillance (AS) remains an important part of the efforts to decrease overtreatment of prostate cancer. The increasing use of magnetic resonance imaging (MRI) can reduce the need for repeat biopsy during AS. If MRI findings remain unchanged and clinical characteristics such as prostate-specific antigen density are favourable, the relative risks and benefits of repeat biopsy should be discussed

The American College of Radiology Vesical Imaging-Reporting and Data System (VI-RADS) Steering Committee will strive to ensure high-quality imaging practices for bladder cancer (BC) and improve outcomes for BC patients. Work will involve evaluation of the current status of magnetic resonance imaging for BC and identify actionable areas to improve its utility in clinical practice. Current VI-RADS gaps